article thumbnail

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). This trial will evaluate the safety of the vaccine and generate efficacy data. Intravacc has received a contract worth $14.6m

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Probiotics increase gut bacteria diversity in extremely preterm infants

Scienmag

A new clinical study has shown that supplements of a lactic acid bacterium may have positive effects by increasing the diversity of intestinal bacteria in these infants. Extremely preterm infants can suffer from a life-threatening inflammation of the gut.

article thumbnail

New Research Shows IBS Symptoms May be Caused by Gut Infections

XTalks

However, IBS patients do not have allergies to any given foods, nor any gastrointestinal conditions, such as celiac disease. Moreover, the response did not induce symptoms typical of a food allergy. This is further proof that the mechanism we have unraveled has clinical relevance,” said Professor Boeckxstaens.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Clinical trials have shown that the vaccine is 90 percent effective in preventing shingles for individuals aged 50 and over. At present, the company has approximately 45 new drugs in Phase II or Phase III clinical trials, or awaiting approval from regulatory authorities in the US, Europe or Japan. billion ($3.65

Sales 98
article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

As of November, the WHO has discouraged the use of the drug as the agency’s review of data from four different clinical trials yielded no worthy effect on mortality, need for mechanical ventilation, time to clinical improvement or any other important patient outcomes. Vaccine Considerations. CRISPR Therapeutics.